Logo of Huzzle

Home

Matches

Explore

Manage

Summer Intern - Clinical Pharmacology

image

Karyopharm Therapeutics Inc.

Jan 23

Applications are closed

  • Internship
    Full-time
    Starts on May 26
    Summer Internship
  • Science

Requirements

  • MS or PhD in Clinical Pharmacology, Pharmacokinetics, Pharmacometrics, Engineering or other suitable post-graduate qualification
  • Experience in the field of clinical pharmacology/pharmacometrics​
  • Strong quantitative skills and expertise in population modeling, exposure response analysis
  • Exposure to tools such as Phoenix WinNonlin, R, Pumas, NONMEM etc.
  • You have a strong interest in life sciences and are passionate about giving patients with cancer a chance to enjoy more of life’s precious moments.
  • You feel a strong connection with our ICARE values (Innovation, Courage, Alignment & Accountability, Resilience, and Energy)
  • You demonstrate enthusiasm for learning and a commitment to career development

Responsibilities

  • A summer internship in Clinical Pharmacology at Karyopharm is an exciting opportunity to apply the knowledge you have gained in the field, think strategically, learn and evaluate new tools to advance decision-making.
  • Learn from scientific mentors to navigate the field of drug development, pharmacometrics and clinical pharmacology
  • Develop pharmacometric models that characterize drug exposure and response (efficacy and safety) relationship
  • Develop approaches to assess and improve model identifiability and evaluate new tools for pharmacometrics analysis
  • Build code repository for data visualizations, projections and simulations
  • Collaborate with data scientists, clinical scientists to provide solutions 

Karyopharm Therapeutics Inc.

Targeting Disease at the Nuclear Pore

Manufacturing & Electronics
Industry
201-500
Employees
2008
Founded Year

Mission & Purpose

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.